Literature DB >> 9051152

Immortalized and tumorigenic adult human prostatic epithelial cell lines: characteristics and applications. Part 3. Oncogenes, suppressor genes, and applications.

M M Webber1, D Bello, S Quader.   

Abstract

This is Part 3 of a three-part review. It deals with the possible role of oncogenes and suppressor genes in human prostate carcinoma as well applications of nontumorigenic and tumorigenic human prostate cell lines described in Parts 1 and 2 [1,2]. Several immortalized and malignant adult human prostatic epithelial cell lines have recently been developed. The three most widely used carcinoma cell lines, DU-145, PC-3, and LNCaP, developed between 1977 and 1980, have greatly contributed to our present understanding of prostate cancer. Before a cell line can be accepted as having prostatic epithelial origin, some basic characteristics must be established. Expression of specific cytokeratins but absence of desmin and factor VIII should be first determined to establish epithelial origin. Responsiveness to androgens and expression of androgen receptor and prostate-specific antigen should be examined under stringent culture conditions to establish prostatic epithelial origin. Response to growth factors and expression of their receptors facilitates further characterization of cell behavior. Cell lines immortalized by human papillomaviruses (HPVs) are of special interest because HPVs are involved in a variety of anogenital cancers and may also play a role in prostate carcinogenesis. Malignant transformation of HPV-18 immortalized cells with the ras oncogene provides cell systems for investigating the multistep process of carcinogenesis. Each cell line has some unique characteristics, whether it arose directly from a carcinoma or resulted from immortalization with simian virus 40 (SV40) or HPV, or was transformed in vitro by oncogenes. Comparisons of these characteristics should facilitate elucidation of the mechanisms involved in initiation, promotion and progression of prostate cancer. These cell lines will further serve as useful models for investigating tumor progression, invasion, metastasis, new therapeutic strategies, drug resistance and its reversal and chemoprevention. This review summarizes some applications of the currently available immortalized, non-tumorigenic as well as the tumorigenic adult human prostatic epithelial cell lines.

Entities:  

Mesh:

Year:  1997        PMID: 9051152     DOI: 10.1002/(sici)1097-0045(19970201)30:2<136::aid-pros9>3.0.co;2-m

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  10 in total

1.  Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms.

Authors:  Mario Menschikowski; Albert Hagelgans; Eugene Gussakovsky; Heike Kostka; Elena L Paley; Gabriele Siegert
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

2.  Immortalized bovine pancreatic duct cells become tumorigenic after transfection with mutant k-ras.

Authors:  M Löhr; P Müller; I Zauner; C Schmidt; B Trautmann; F Thévenod; G Capellá; A Farré; S Liebe; R Jesenofsky; R Jesnowski
Journal:  Virchows Arch       Date:  2001-06       Impact factor: 4.064

3.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

4.  Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6.

Authors:  Janeen Azare; Kenneth Leslie; Hikmat Al-Ahmadie; William Gerald; Paul H Weinreb; Shelia M Violette; Jacqueline Bromberg
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

5.  EPN: a novel epithelial cell line derived from human prostate tissue.

Authors:  Antonio A Sinisi; Paolo Chieffi; Daniela Pasquali; Annamaria Kisslinger; Stefania Staibano; Antonio Bellastella; Donatella Tramontano
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-03       Impact factor: 2.416

Review 6.  Chemoprevention of carcinoma prostate: a review.

Authors:  M S Ansari; N P Gupta; A K Hemal
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

7.  PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis.

Authors:  Kexiong Zhang; David J Waxman
Journal:  Mol Cancer       Date:  2010-12-29       Impact factor: 27.401

8.  A genome-wide RNAi screen identifies FOXO4 as a metastasis-suppressor through counteracting PI3K/AKT signal pathway in prostate cancer.

Authors:  Bing Su; Lingqiu Gao; Catherine Baranowski; Bryan Gillard; Jianmin Wang; Ryan Ransom; Hyun-Kyung Ko; Irwin H Gelman
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

9.  In search of the molecular mechanisms mediating the inhibitory effect of the GnRH antagonist degarelix on human prostate cell growth.

Authors:  Monica Sakai; Daniel B Martinez-Arguelles; Nathan H Patterson; Pierre Chaurand; Vassilios Papadopoulos
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

10.  Plumbagin-induced apoptosis in human prostate cancer cells is associated with modulation of cellular redox status and generation of reactive oxygen species.

Authors:  Anna A Powolny; Shivendra V Singh
Journal:  Pharm Res       Date:  2008-01-23       Impact factor: 4.580

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.